Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 8/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 5/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | APEX1 | P27695 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4907422 | 0.92 | MCL1 (0.41) | MCL1BCL2L1POLBLMNAHTT | |
| SCHEMBL4905862 | 0.92 | POLB (0.41) | MCL1BCL2L1POLBLMNAHTT | |
| SCHEMBL4902549 | 0.91 | LMNA (0.38) | MCL1BCL2L1POLBLMNAHTT | |
| SCHEMBL4902601 | 0.91 | ALDH1A1 (0.38) | TDP1LMNAHTTSMN1; SMN2NPC1 | |
| SCHEMBL4906155 | 0.90 | MCL1 (0.35) | MCL1BCL2L1POLBLMNAHTT | |
| SCHEMBL4908223 | 0.90 | TAS2R14 (0.36) | MCL1BCL2L1POLBLMNAHTT | |
| SCHEMBL4905724 | 0.90 | POLB (0.43) | TDP1MCL1BCL2L1POLBLMNA | |
| SCHEMBL4895687 | 0.89 | L3MBTL1 (0.39) | MCL1BCL2L1POLBLMNAHTT | |
| SCHEMBL4902692 | 0.88 | MCL1 (0.39) | MCL1BCL2L1POLBAPEX1CTDSP1 | |
| SCHEMBL4906808 | 0.88 | MMP9 (0.36) | MCL1BCL2L1LMNAHTTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288340-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | TDP1 3653/4885MCL1 4319/4885BCL2L1 2219/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | TDP1 3653/4885MCL1 4319/4885BCL2L1 2219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.